Navigation Links
Some Face Transplant Patients May Regain Sensory, Motor Function
Date:10/26/2012

FRIDAY, Oct. 26 (HealthDay News) -- Within a year after having face transplant surgery, some patients regain sensory and motor functions such as the ability to speak, chew food and smile, experts have found.

For the study, Dr. Bohdan Pomahac, director of the plastic surgery transplantation program at Brigham & Women's Hospital in Boston, and colleagues assessed the return of sensory and motor functions in four patients who had full or partial face transplants between 2009 and 2011.

Initially, the transplant patients could not breathe through their new mouth or nose and required a breathing tube. They were also unable to speak or chew, and could not sense objects touching the surface of their skin.

But one year after the transplant, some of the patients could breathe, eat and talk quite easily. They also regained their sense of smell, were able to make facial expressions and could do some socializing, the investigators found.

These successes depended on whether major nerves in the body were able to be reconnected with those in the transplanted face, the researchers noted. In some patients, severe damage from their original injuries made it impossible to reconnect nerves in some areas.

The study was scheduled for presentation Saturday at the American Society of Plastic Surgeons' annual meeting in New Orleans.

"What we found is that a face transplant is more than a way to create a more pleasing appearance because the new face can be functional as well," Pomahac, who is also an ASPS member surgeon, said in a society news release.

The data and conclusions of research presented at medical meetings should be viewed as preliminary until published in a peer-reviewed journal.

More information

The American Academy of Facial Plastic and Reconstructive Surgery has more about face transplantation.'/>"/>

Copyright©2012 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Discovery could help to develop drugs for organ transplant and cancer patients
2. Xenotransplantation as a therapy for type 1 diabetes
3. First, Second Kidney Transplants Have Similar Success: Study
4. Lenalidomide prolongs disease control for multiple myeloma patients after stem cell transplant
5. Statins prevent cancer in heart transplant recipients
6. U.S. Liver Transplants Declining
7. Study shows antibiotic improves respiratory function in lung transplant patients
8. UCLA launches first face transplantation program in western US
9. Use of Smokers Lungs for Transplant Has Pros, Cons
10. Skin transplant offers new hope for vitiligo patients
11. Haematopoietic stem cell transplantation increases survival in systemic sclerosis patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Some Face Transplant Patients May Regain Sensory, Motor Function 
(Date:10/2/2014)... at The University of Nottingham could lead to the ... A drug resulting from the research, published in the ... hope to sufferers of chronic pain conditions such as ... currently available. , The work, led by Dr Lucy ... collaboration with David Bates, Professor of Oncology in the ...
(Date:10/1/2014)... shown that more than 80 per cent of bowel ... study found that medicines called ,JAK inhibitors, halted tumour ... is present in more than 80 per cent of ... are in clinical trials, for diseases including rheumatoid arthritis, ... is the second-most common cancer in Australia with nearly ...
(Date:10/1/2014)... New research co-funded by the Engineering and Physical ... cyber-security of the UK,s vital industrial control systems ... the electricity grid, and the rail network. ... threats from hackers or malware infiltrating the systems ... Research Institute in Trustworthy Industrial Control Systems (RITICS), ...
(Date:10/1/2014)... suggests the adage that encourages people to keep their ... it comes to exercise. When walking, staying focused on ... it appear shorter and help people walk there faster, ... technique to walking while looking around the environment naturally, ... exercise. , "People are less interested in exercise if ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Insuranceragents.info ... find a good life insurance plan for vulnerable family ... for vulnerable family members. Providers in the family should ... will cause financial hardships for the rest of the ... of policies. Families can benefit more from temporary coverage ...
Breaking Medicine News(10 mins):Health News:Medical discovery first step on path to new painkillers 2Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2
... New findings about brain rhythms could lead to the development ... team at Massachusetts General Hospital found that a brain rhythm ... form during sleep, where it becomes more intense at certain ... being awakened by noise or other disturbances. To test ...
... (ASM) will hold its 111th General Meeting May ... meeting will feature approximately 3,000 individual scientific presentations ... expected attendance of 10,000. Microbiologists study living ... critical to human and animal health, agriculture, the ...
... a common but painful deformity of the foot, are more likely ... found. And the more severe the bunion, the more likely ... body, leading to declines in both general and foot-specific health-related quality ... develops on the side of the big toe as it leans ...
... have discovered that a natural product isolated from a traditional ... lei gong teng, and used for hundreds of years to ... control machinery in the cell. The report, published as a ... Biology, suggests that the natural product could be a ...
... HealthDay Reporter , THURSDAY, March 3 (HealthDay News) ... painkillers experience cognitive problems such as confusion, disorientation and ... cancer patients from 17 health-care centers around Europe indicated ... morphine scored lower on observer-rated mental tests measuring orientation ...
... vast literature on cancer to produce a next-generation view ... cells. These hallmarks of the disease provide a ... influence biomedical researchers in their quest for new cancer ... Hanahan of cole Polytechnique Fdrale in Switzerland and Robert ...
Cached Medicine News:Health News:Particular Brain Rhythm in Sleep Makes You More Vulnerable to Disturbances 2Health News:American Society for Microbiology to host 111th General Meeting in New Orleans 2Health News:Solving a traditional Chinese medicine mystery 2Health News:Solving a traditional Chinese medicine mystery 3Health News:Study Finds Third of Cancer Patients on Opioids Are Confused 2Health News:Study Finds Third of Cancer Patients on Opioids Are Confused 3Health News:In search of cancer's common ground: A next-generation view 2
(Date:10/2/2014)... Oct. 2, 2014   Softworld, Inc. announced today ... practice solely focused on the specific needs of pharmaceutical, ... Softworld has already been highly successful in the clinical ... capabilities to support the quality, regulatory, and validation space. ... a combination of the current Biometric team and the ...
(Date:10/2/2014)... 2, 2014   Mast Therapeutics, Inc. (NYSE ... Edwin L. Parsley , D.O. has joined the ... President.  Dr. Parsley has been actively engaged ... in February 2014.  He has served as Mast,s interim ... Medical Officer of Aires since April 2011.  Dr. Parsley ...
(Date:10/2/2014)... BOSTON , Oct. 1, 2014   Intarcia ... two of its four phase 3 clinical trials for ... through a matchstick-sized, subcutaneous osmotic mini-pump). The first trial, ... that tested the efficacy and safety of ITCA 650 ... study demonstrated ITCA 650 to be significantly superior to ...
Breaking Medicine Technology:Softworld, Inc. Launches Strategic Division Dedicated to Life Sciences Consulting 2Mast Therapeutics Announces Appointment Of Chief Medical Officer 2Mast Therapeutics Announces Appointment Of Chief Medical Officer 3Mast Therapeutics Announces Appointment Of Chief Medical Officer 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5
... (Logo: http://photos.prnewswire.com/prnh/20110616/NY20158LOGO)Q2 2011 Change on a , ... exchange rates(1) , H1 2011Change on a , ... , exchange ratesNet sales , euro 8,349m+0.5% , +6.9% , ... , -7.0% , euro 4,320m-11.9% , -11.5%Business EPS (1) , ...
... 2011 Cell Therapeutics, Inc. ("CTI" or the "Company") (NASDAQ ... develop its late stage oncology pipeline to market coupled with ... 2011. "In the second quarter, we seized on ... of New Drugs ("OND") in allowing us to resubmit the ...
Cached Medicine Technology:Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 2Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 3Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 4Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 5Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 6Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 7Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 8Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 9Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 10Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 11Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 12Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 13Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 14Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 15Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 16Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 17Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 18Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 19Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 20Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 21Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 22Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 23Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 24Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 25Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 26Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 27Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 28Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 29Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 30Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 31Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 32Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 33Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market 2Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market 3Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: